Satellos Bioscience Inc Financials
This page shows Satellos Bioscience Inc (MSLE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Satellos Bioscience Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Satellos Bioscience Inc carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.77, Satellos Bioscience Inc holds $7.77 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Satellos Bioscience Inc generates a -89.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -43.8% the prior year.
Satellos Bioscience Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Satellos Bioscience Inc generates $0.95 in operating cash flow (-$23.6M OCF vs -$24.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Satellos Bioscience Inc reported -$24.9M in net income in fiscal year 2025. This represents a decrease of 20.5% from the prior year.
Cash & Balance Sheet
Satellos Bioscience Inc generated -$23.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 29.3% from the prior year.
Satellos Bioscience Inc held $9.8M in cash against $0 in long-term debt as of fiscal year 2025.
Satellos Bioscience Inc had 15M shares outstanding in fiscal year 2025.
Margins & Returns
Satellos Bioscience Inc's ROE was -89.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 45.8 percentage points from the prior year.
Capital Allocation
Satellos Bioscience Inc invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 50.0% from the prior year.
MSLE Income Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
MSLE Balance Sheet
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $31.9M-37.2% | $50.7M+51.5% | $33.5M |
| Current Assets | $31.9M-37.2% | $50.7M+66.5% | $30.5M |
| Cash & Equivalents | $9.8M-75.5% | $40.1M+140.2% | $16.7M |
| Inventory | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $4.1M+14.6% | $3.6M+31.1% | $2.7M |
| Current Liabilities | $4.1M+14.6% | $3.6M+31.1% | $2.7M |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | $27.8M-41.1% | $47.2M+53.3% | $30.8M |
| Retained Earnings | -$82.0M-43.6% | -$57.1M-56.6% | -$36.5M |
MSLE Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
MSLE Financial Ratios
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 7.77-6.4 | 14.16+3.0 | 11.15 |
| Debt-to-Equity | 0.15+0.1 | 0.08-0.0 | 0.09 |
| FCF Margin | N/A | N/A | N/A |
Frequently Asked Questions
Is Satellos Bioscience Inc profitable?
No, Satellos Bioscience Inc (MSLE) reported a net income of -$24.9M in fiscal year 2025.
What is Satellos Bioscience Inc's return on equity (ROE)?
Satellos Bioscience Inc (MSLE) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Satellos Bioscience Inc's free cash flow?
Satellos Bioscience Inc (MSLE) generated -$23.6M in free cash flow during fiscal year 2025. This represents a -29.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Satellos Bioscience Inc's operating cash flow?
Satellos Bioscience Inc (MSLE) generated -$23.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Satellos Bioscience Inc's total assets?
Satellos Bioscience Inc (MSLE) had $31.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Satellos Bioscience Inc's capital expenditures?
Satellos Bioscience Inc (MSLE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Satellos Bioscience Inc's current ratio?
Satellos Bioscience Inc (MSLE) had a current ratio of 7.77 as of fiscal year 2025, which is generally considered healthy.
What is Satellos Bioscience Inc's debt-to-equity ratio?
Satellos Bioscience Inc (MSLE) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Satellos Bioscience Inc's return on assets (ROA)?
Satellos Bioscience Inc (MSLE) had a return on assets of -78.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Satellos Bioscience Inc's cash runway?
Based on fiscal year 2025 data, Satellos Bioscience Inc (MSLE) had $9.8M in cash against an annual operating cash burn of $23.6M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Satellos Bioscience Inc's Piotroski F-Score?
Satellos Bioscience Inc (MSLE) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Satellos Bioscience Inc's earnings high quality?
Satellos Bioscience Inc (MSLE) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Satellos Bioscience Inc?
Satellos Bioscience Inc (MSLE) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.